MULTIPLE SCLEROSIS, RELAPSING-REMITTING

This phase III trial is testing whether a long-acting form of glatiramer acetate, called GA Depot, given as a monthly injection, can reduce the number of relapses in people with relapsing-remitting multiple sclerosis (MS). The study involves about 1,000 adults aged 18 to 55 with …

This trial tests whether cladribine tablets change key immune cells and nerve damage markers in the spinal fluid of people with relapsing forms of multiple sclerosis. Participants take cladribine as prescribed and undergo up to two lumbar punctures to measure these biomarkers ove…

This study investigates whether chiropractic spinal manipulation can reduce inflammation and improve symptoms in people with relapsing-remitting multiple sclerosis (MS). Participants receive either real or sham spinal adjustments over four weeks. Researchers measure changes in bl…

This study tested a treatment called extracorporeal photopheresis (ECP) in 15 people with multiple sclerosis. ECP is a procedure that filters a person's blood, treats it with light, and returns it to the body. The goal was to see if it is safe and if it can improve walking, hand …

This phase 2 trial tested clemastine fumarate, a common allergy medicine, to see if it could repair damaged nerves in people with relapsing-remitting multiple sclerosis. Fifty participants took either the drug or a placebo for several months. The study measured nerve signals in t…

This study followed 450 people with relapsing-remitting multiple sclerosis (RRMS) in Germany who were already prescribed ozanimod (Zeposia). Over three years, researchers collected data on how long patients stayed on the drug, its effect on quality of life, and any side effects. …

This study tests whether adding task-oriented training—like walking on different surfaces, climbing stairs, and reaching for objects—to standard aerobic and strength exercises can improve functional mobility, balance, and fatigue in people with relapsing-remitting multiple sclero…

This study investigates whether disease-modifying medications for relapsing-remitting multiple sclerosis (RRMS) can reduce cognitive fatigue—the tiredness that follows intense mental effort. Researchers will use functional MRI to measure brain activation in people starting either…

This study explores whether the medication Tysabri can reduce cognitive fatigue—the tiredness that comes after intense mental effort—in people with relapsing-remitting multiple sclerosis (RRMS). Researchers will compare brain activity, measured with functional MRI, between RRMS p…

This study follows people with relapsing-remitting multiple sclerosis who are starting immunosuppressant treatment. Researchers will track changes in cognitive abilities, fatigue, emotions, and overall quality of life over an extended period. The goal is to better understand how …

This completed study looked at 75 people with relapsing-remitting multiple sclerosis (RRMS) who were taking the medication Aubagio. The goal was to see if virtual reality tests and real-world tasks could better detect cognitive (thinking) problems in everyday life compared to sta…

This study looked at 94 people with relapsing-remitting multiple sclerosis to better understand why standard MRI scans often don't match a person's actual walking ability. Researchers used advanced MRI to measure damage in brain and spinal cord pathways important for movement and…

This study looked at 104 people with relapsing-remitting multiple sclerosis (RRMS) who switched their disease-modifying therapy to ozanimod. Researchers tracked why they switched (e.g., lack of effectiveness, side effects) and how the switch was done. The goal was to understand r…